Product Description
4P004 is a GLP-1 analog, a potential first-in-class disease modifier drug for osteoarthritis (DMOAD), showing anti-inflammatory, anti-catabolic and anabolic properties. (Sourced from: https://4p-pharma.com/#pipeline)
Mechanisms of Action: GLP-1 Analogue
Novel Mechanism: Yes
Modality: N/A
Route of Administration: N/A
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: 4Moving Biotech
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Belgium
Active Clinical Trial Count: 1
Highest Development Phases
Phase 1: Osteoarthritis, Knee
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| LASARE | P1 |
Completed |
Osteoarthritis, Knee |
2023-10-31 |